USPTO serial 97530188
TALK. TEXT. SHARE.
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 16, 2024
- Examiner
- BROOKSHIRE, DAVID AARON
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with TALK. TEXT. SHARE.?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Erin C Bray
Erin C Bray TRADEMARK LAWYER LAW FIRM, PLLCP.O. BOX 512ANN ARBOR, MI 48106-0512United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Platform as a service (PAAS) featuring computer software platforms for IT Solutions for Healthcare, Medical Devices, pharmaceutical and biotech industries, namely, Mobile Application to Record Interactions with Healthcare Professionals, patients, healthcare organizations Including Physicians, Patients, Payers, Providers and Providing Representatives an Ability to View Media Content and Reports, Web and Mobile Portals For Patients to Find Information on Drugs and Connect with Pharma Companies, Web and Mobile Portals For Physicians to Find Information on Drugs and Connect with Pharma Companies, Mobile and Web Application to Providing Reporting and Analytics Capabilities Using Various Data Sources; Providing temporary use of non-downloadable cloud based software featuring computer software platforms for IT Solutions for Healthcare, Medical Devices pharmaceutical and biotech industries, namely, Sales Force Automation to log interactions with health care professionals including physicians, Patients, Payers, Providers, Customer Relationship Management application to manage Contacts, Accounts, Opportunities, Orders and other custom entities, Maintain operational customer master and integrate with other applications, Application to manage all phases of clinical trials including Site Management and Study Management, Application to provide patients with complete support during the course of therapy from the time of prescription including welcome call, Benefit Investigations, Trial Orders, Prior Authorization; Providing temporary use of online non-downloadable Analytics and Planning software providing advanced analytics using machine learning, Internet of Things (IoT), and artificial intelligence to support interactions between pharma, biotech, and med devices companies, physicians, payers, and providers; software as a service (SAAS) services featuring Analytics and Planning software providing advanced analytics using machine learning, Internet of Things (IoT), and artificial intelligence to support interactions between pharma/biotech/med devices companies, physicians, payers, and providers; Platform as a service (PAAS) featuring conversational artificial intelligence for call filtering, call monitoring, making audio and video calls, co-browse, SMS and email alerts, sales tracking, attribution measurement, marketing and sales optimization, and customer service to support interactions between pharmaceuticals, biotechnology, and medical devices companies, physicians, patients, payers, and providers, and other healthcare workers; Software as a Services (SAAS) featuring conversational artificial intelligence for call filtering, call monitoring, making audio and video calls, co-browse, SMS and email alerts, sales tracking, attribution measurement, marketing and sales optimization, and customer service to support interactions between pharmaceuticals, biotechnology, and medical devices companies, physicians, patients, payers, and providers, and other healthcare workers | ACTIVE | May 10, 2022 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 25, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 25, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 25, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 25, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jun 25, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jan 22, 2024 | NRCS | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 17, 2024 | NRCS | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 16, 2024 | NRCS | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 16, 2024 | R.SR | REGISTERED-SUPPLEMENTAL REGISTER | Your mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application. |
| Aug 24, 2023 | CNTA | APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER | — |
| Jun 20, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 20, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 20, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 20, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 20, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 20, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 19, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 19, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 19, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 19, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 23, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 5, 2022 | NWAP | NEW APPLICATION ENTERED | — |